RESOURCES
EOHILIA At a Glance
Provides an overview of EOHILIA including dosing and administration, efficacy, and safety profile information.
Patient Profiles
EOHILIA is appropriate for a broad range of patients with EoE 11 years and older with variability in medical history. It offers the same reliable dosing for different patient types. See patient profiles to learn more.
Dysphagia Symptom Questionnaire (DSQ)
The DSQ tool was used in the EOHILIA clinical studies to evaluate dysphagia symptom response. Visit the clinical efficacy page to learn more.
Endoscopic Reference Score (EREFS)
The EREFS is a standardized tool used to classify and grade the presence and severity of the 5 major endoscopic features of EoE. Thresholds for clinically meaningful changes in the EoE-EREFS have not been established.2 Visit the clinical efficacy page to learn more.
Letter of Medical Exception (LME)
EOHILIA is an FDA-approved medication that may not yet be covered by insurance companies. Healthcare providers should submit an LME to the patient’s insurance provider to support a patient’s access to EOHILIA. Visit the patient access page for more information.
Letter of Appeal (LOA)
If your patient is denied coverage by their insurance plan, you can appeal the decision by detailing your choice to prescribe EOHILIA in an LOA. This letter typically acknowledges each specific reason given for the denial and then follows up with the clinical rationale for prescribing EOHILIA in the patient’s case. Prior Authorization (PA) denial and appeal processes vary by health plan and may be conducted through letter correspondence, fax, or peer-to-peer discussion. Visit the patient access page for more information.
Prior Authorization Overview
To support patient access to EOHILIA, healthcare providers may be required to obtain a PA with an LME. Consider using this overview as a guide when submitting a PA, LME, or LOA. Visit the patient access page for more information.
EOHILIA Starter Kit
The EOHILIA Starter Kit provides the most important information your patients need to get started with their treatment. Patients can get an understanding of how EOHILIA works, what to expect when taking it, and how to take a dose as well as information on the patient support and copay program. Visit the getting started page to learn more.
EOHILIA Patient Brochure
The EOHILIA Patient Brochure is designed to help your patients learn about EoE and how EOHILIA may be able to help. It’s full of information about the underlying causes of EoE as well as in-depth information on how treatment with EOHILIA works. Visit the getting started page to learn more.
Copay FAQ Guide
The Copay FAQ Guide answers all the important questions your patients may have about costs, savings, and coverage for EOHILIA. Visit the support + copay page for more information.
Doctor Discussion Guide
The Doctor Discussion Guide is designed to help doctors and patients have a more productive conversation. The guide can help patients organize their thoughts and better understand their experience managing EoE before their visit. This useful tool can help doctors and patients get on the same page with a treatment plan. Visit the getting started page to learn more.
EOHILIA Animation Video
The EOHILIA Animation Video provides a visual explanation of thixotropy and what makes EOHILIA different in the way it treats EoE. It also includes a closer look at the reliable dosing EOHILIA provides and how patients can take it on the go. Watch the video to learn more.
How to Take EOHILIA
This video provides a short demonstration of EOHILIA's Instructions for Use.
References:
- EOHILIA (budesonide oral suspension) Prescribing Information. Takeda Pharmaceuticals, Inc.
- Lucendo AJ, Molina-Infante J, Arias A, et al. United European Gastroenterol J. 2017:5(3):335-358.
VIDEO TRANSCRIPT
While eosinophilic esophagitis (EoE) symptoms are unique in each patient, the underlying cause is esophageal inflammation, due to an increase in eosinophils in the esophagus.
That’s why it’s important to treat inflammation where it occurs.
EOHILIA (budesonide oral suspension) is a corticosteroid indicated for 12 weeks of treatment in patients 11 years and older with EoE. EOHILIA has not been shown to be safe and effective for longer than 12 weeks. EOHILIA is contraindicated for patients with hypersensitivity to budesonide. Serious hypersensitivity reactions, including anaphylaxis, have occurred with oral budesonide products. Please continue watching until the end of the video for full Important Safety Information.
EOHILIA is specifically designed for EoE.
It is the first and only oral 12-week, FDA-approved treatment.
Indicated for people with EoE 11 years and older.
EOHILIA is designed with a viscosity that can change. At rest, EOHILIA is highly viscous. Upon shaking, it gets more fluid; and then regains viscosity to flow slower.
The ability to go from low to high viscosity is known as thixotropy.
This physical property creates a novel budesonide formulation.
EOHILIA is designed to fit into patients’ pockets and their daily routines, with a twice-daily 12-week dosing regimen.
It is ready for on-the-go use in pre-prepared, single-dose stick packs with no mixing, measuring, or refrigeration required.
Remind your patients that EOHILIA should be taken as prescribed:
2 mg twice daily, once in the morning and once in the evening, for 12 weeks.
EOHILIA. Designed for EoE. Treat inflammation where it occurs.
VIDEO TRANSCRIPT
EOHILIA (budesonide oral suspension) is a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EOE). EOHILIA has not been shown to be safe and effective for treatment of EOE for longer than 12 weeks. EOHILIA is contraindicated in patients with hypersensitivity to budesonide. Serious hypersensitivity reactions, including anaphylaxis, have occurred with oral budesonide products. Please see important safety information at the end of this video.
In this video we'll show you how EOHILIA is taken. EOHILIA is the first and only FDA approved oral 12 week treatment for EoE for patients 11 years and older. EOHILIA was assessed in two 12 week trials evaluating histological remission and reduction of dysphagia. Visit EOHILIAHCP.com to see the data.
First, inspect the package and do not take if the carton seal is broken, or if the packet is damaged or leaking, or the expiration date has passed. Now take the packet out of the box and shake it for 10 seconds.
No mixing, measuring, or refrigeration required.
At rest EOHILIA is highly viscous. Upon shaking, it becomes less viscous for swallowing. Then EOHILIA regains its viscosity to flow slower. That's called thixotropy. Thixotropy is an example of how EOHILIA was designed for EOE.
Using scissors cut along the dotted line straight across the top of the packet.
Each packet reliably contains the recommended two milligram dose of budesonide, the active ingredient in EOHILIA. EOHILIA is pre-mixed and taken directly from the packet. Take EOHILIA by squeezing the packet from the bottom to the top directly into the mouth. Make sure to squeeze it two or three times to get all the medicine out. Don't take EOHILIA with food or liquid.
The empty packet can be thrown into the trash.
Patients should not eat or drink anything for at least 30 minutes after taking EOHILIA.
Setting a timer can be a helpful way for patients to keep track.
After 30 minutes, the patient rinses their mouth with water and spits out the contents without swallowing.
EOHILIA is recommended to be taken twice a day, once in the morning, and once at night. No mixing or measuring means it fits into your patients' schedules, whether they're home for the day or on the go.